CPRX
HEALTHCARECatalyst Pharmaceuticals Inc
AI Insight
What's Moving CPRX Today?
No stock-specific AI insight has been generated for CPRX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$19.05$32.56
$31.40
Fundamentals
Market Cap$3.8B
P/E Ratio18.1
EPS$1.73
Dividend Yield—
Dividend / Share—
ROE24.5%
Profit Margin37.1%
Debt / Equity—
Trading
Volume949K
Avg Volume (10D)—
Shares Outstanding122.4M
CPRX News
23 articles- Catalyst (CPRX) Up 0.6% Since Last Earnings Report: Can It Continue?Yahoo Finance·Jun 10, 2026
- GlobeFlex Exits NCR Atleos After Brink’s Buyout DealMotley Fool·May 20, 2026
- Angelini Buyout And FIRDAPSE Settlement Reframe Catalyst Pharmaceuticals StoryYahoo Finance·May 20, 2026
- CPRX or UTHR: Which Is the Better Value Stock Right Now?Yahoo Finance·May 14, 2026
- Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/YYahoo Finance·May 12, 2026
- Catalyst (CPRX) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesYahoo Finance·May 11, 2026
- Catalyst Pharmaceutical (CPRX) Surpasses Q1 Earnings and Revenue EstimatesYahoo Finance·May 11, 2026
- Catalyst Pharmaceuticals Reports First Quarter 2026 Financial ResultsYahoo Finance·May 11, 2026
- Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRXThe AI Journal·May 11, 2026
- Angelini Pharma agrees $4.1bn Catalyst Pharmaceuticals acquisitionInvestmentmonitor·May 11, 2026
- Catalyst Pharmaceuticals Buyout And FIRDAPSE Patents Reframe Investor OutlookYahoo Finance·May 10, 2026
- This Biotech Stock Has Soared 175%. Here’s Why One Fund Still Sold $3 Million WorthMotley Fool·May 9, 2026
- Angelini Pharma acquires Catalyst Pharmaceuticals for $4.1 billionQz·May 8, 2026
- Angelini Pharma to acquire Catalyst Pharmaceuticals for equity value of $4.1bnHospitalmanagement·May 8, 2026
- Catalyst Pharmaceuticals Cancels First Quarter 2026 Conference Call and WebcastYahoo Finance·May 7, 2026
- Sector Update: Health Care Stocks Softer Late AfternoonYahoo Finance·May 7, 2026
- UTHR Q1 Earnings Miss Estimates, Shares Jump on Strong OutlookYahoo Finance·May 7, 2026
- ACAD Q1 Earnings & Revenues Miss Estimates Despite Y/Y Sales GrowthYahoo Finance·May 7, 2026
- Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock UpYahoo Finance·May 7, 2026
- RXRX Q1 Loss Narrower Than Expected, Revenues Decline Y/YYahoo Finance·May 7, 2026
- Seeking Clues to Catalyst (CPRX) Q1 Earnings? A Peek Into Wall Street Projections for Key MetricsYahoo Finance·May 7, 2026
- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Hetero Labs Ltd.GlobeNewswire Inc.·May 7, 2026
- Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare DiseaseBenzinga·May 7, 2026
All 23 articles loaded
Price Data
Open$31.39
Previous Close$31.40
Day High$31.40
Day Low$31.37
52 Week High$32.56
52 Week Low$19.05
52-Week Range
$19.05$32.56
$31.40
Fundamentals
Market Cap$3.8B
P/E Ratio18.1
EPS$1.73
Dividend Yield—
Dividend / Share—
ROE24.5%
Profit Margin37.1%
Debt / Equity—
Trading
Volume949K
Avg Volume (10D)—
Shares Outstanding122.4M
About Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, neuromuscular, and chronic neurological diseases in the United States. The company is headquartered in Coral Gables, Florida.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—